Immunomedics (IMMU) vs. Arsanis (ASNS) Financial Survey

Arsanis (NASDAQ: ASNS) and Immunomedics (NASDAQ:IMMU) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Arsanis and Immunomedics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arsanis N/A N/A -$33.88 million ($2.05) -11.76
Immunomedics $3.09 million 869.09 -$153.20 million ($1.86) -8.71

Arsanis has higher earnings, but lower revenue than Immunomedics. Arsanis is trading at a lower price-to-earnings ratio than Immunomedics, indicating that it is currently the more affordable of the two stocks.


This table compares Arsanis and Immunomedics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arsanis N/A N/A N/A
Immunomedics -7,187.83% N/A -76.04%

Institutional and Insider Ownership

72.5% of Arsanis shares are held by institutional investors. Comparatively, 74.5% of Immunomedics shares are held by institutional investors. 14.8% of Immunomedics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Arsanis and Immunomedics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arsanis 0 0 4 0 3.00
Immunomedics 0 0 3 0 3.00

Arsanis presently has a consensus target price of $25.33, suggesting a potential upside of 5.07%. Immunomedics has a consensus target price of $21.00, suggesting a potential upside of 29.63%. Given Immunomedics’ higher probable upside, analysts clearly believe Immunomedics is more favorable than Arsanis.


Immunomedics beats Arsanis on 6 of the 10 factors compared between the two stocks.

Arsanis Company Profile

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV).

Immunomedics Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with's FREE daily email newsletter.

Leave a Reply